Stocktoria
Cullinan Therapeutics, Inc. CGEM
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-01-08
Cullinan Therapeutics, Inc. statistics & valuation
Market cap$1.1B
P / B2.8×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | — | — | — | — | -358.7% |
| Net margin | — | — | — | — | -346.1% |
| FCF margin | — | — | — | — | -229.3% |
| Return on assets | -49.0% | -26.9% | -31.6% | 19.8% | -15.0% |
| Return on equity | -53.8% | -28.4% | -33.7% | 20.8% | -15.4% |
| Current ratio | 10.25 | 13.53 | 17.07 | 21.09 | 25.25 |
| Revenue growth | — | — | — | -100.0% | — |
Source: SEC EDGAR filings · CIK 0001789972 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.